https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22587 0.75, n=7), and healthy controls (HC) (n=9) were stimulated with bacterial (LPS (1 g/mL), fMLF (100 nM)), and viral (imiquimod (3 g/mL), R848 (1.5 g/mL), and poly I:C (10 g/mL)) surrogates or live rhinovirus (RV) 16 (MOI1). Cell-free supernatant was collected after 1 h for neutrophil elastase (NE) and matrix metalloproteinase- (MMP-) 9 measurements or after 24 h for CXCL8 release. Results: Constitutive NE was enhanced in AGood neutrophils compared to HC. fMLF stimulated neutrophils from ASubopt but not AGood produced 50% of HC levels. fMLF induced MMP-9 was impaired in ASubopt and AGood compared to HC. fMLF stimulated CXCL8 but not MMP-9 was positively correlated with FEV1 and FEV1/FVC. ASubopt and AGood responded similarly to other stimuli. Conclusions: Circulating neutrophils are different in asthma; however, this is likely to be related to airflow limitation rather than asthma control.]]> Wed 11 Apr 2018 14:23:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2979 Wed 11 Apr 2018 12:34:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22540 Wed 11 Apr 2018 10:17:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54624 Wed 06 Mar 2024 10:53:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26006 Wed 06 Apr 2022 14:02:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31201 Wed 02 Mar 2022 14:27:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47636 Tue 24 Jan 2023 14:30:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25524 29 parts per billion (ppb), decrease in dose when FENO <19 ppb, and no change when FENO is between 19 and 29 ppb). A long acting beta agonist (LABA) will be added when symptoms remain uncontrolled. Both the control and intervention groups will report on exacerbations at a postpartum phone interview. The primary outcome is adverse perinatal outcome (a composite measure including preterm birth, intrauterine growth restriction, neonatal hospitalisation at birth or perinatal mortality), assessed from hospital records. Secondary outcomes will be each component of the primary outcome, maternal exacerbations requiring medical intervention during pregnancy (both smokers and non-smokers), and hospitalisation and emergency department presentation for wheeze, bronchiolitis or croup in the first 12 months of infancy. Outcome assessment and statistical analysis of the primary outcome will be blinded. To detect a reduction in adverse perinatal outcomes from 35 % to 26 %, 600 pregnant women with asthma per group are required. Discussion: This trial will provide evidence for the effectiveness of a FENO-based management strategy in improving perinatal outcomes in pregnant women with asthma. If successful, this would improve the management of pregnant women with asthma worldwide.]]> Thu 17 Mar 2022 14:41:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32186 Thu 13 Jan 2022 10:28:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29169 p = 0.480) and uncontrolled asthma at =2 study visits (21.3-11.3%; p = 0.078). Conclusions: These findings demonstrate the potential impact of an AMS in improving asthma control during pregnancy, supporting the need for an adequately powered RCT to determine its clinical- and cost-effectiveness.]]> Sat 24 Mar 2018 07:35:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4776 Sat 24 Mar 2018 07:20:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37810 Mon 31 Jan 2022 15:14:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44479 Fri 14 Oct 2022 08:50:25 AEDT ]]>